Dr. Blair Keagy Launches MPAnalytics, Inc. Medical Consultant Group
Published: Nov 17, 2008
MPAnalytics provides market analysis and recommendations for new medical devices and technology based on five key parameters: scientific merit, reimbursement potential, competition and clinical potential, practical market potential and clinical trial analysis. The founders of MPAnalytics have extensive clinical experience as well as knowledge of clinical trial design, reimbursement issues and practical markets for new medical devices and technologies.
Dr. Blair Keagy, former Chief of Vascular Surgery at the University of North Carolina, has authored numerous articles as well as a textbook on healthcare economics and is considered an expert on medical reimbursement.
“I credit my colleagues at the UNC School of Medicine and the Kenan-Flaghler Launching the Venture Program with helping to get this business off the ground,” states Dr. Keagy. “Now, we have clients enthusiastically soliciting our help in assessing the business potential of their new medical devices or ideas before investing significant monies in development or clinical trial.”
Ted Zoller, Executive Director, UNC Center for Entrepreneurial Studies describes MPAnalytics as “an excellent example of the type of entrepreneurial venture that we hope will emerge from our program. Blair and his team have great medical expertise. MPA’s assessment of commercial potential and their depth of market analysis are far better than the typical medical advisory board can provide.”
The MPAnalytics team combines their competence in medical research and the life sciences marketplace with the business savvy necessary to create a medical consultant group that provides great value to medical device companies and investor groups.
For more information about MPAnalytics,Inc. please contact contact Blair Keagy at email@example.com , call 919.873.4047, or visit www.MPAnalytics.com.
MPAnalytics Blair Keagy, 919-873-4047 firstname.lastname@example.org www.MPAnalytics.com
Source: MPAnalytics, Inc.